[go: up one dir, main page]

CL2008003122A1 - Use of an anti-cd20 type II antibody useful to prepare a drug to treat a cancer that expresses cd20 in combination with a proteasome inhibitor, pharmaceutical composition containing said combination and kit of the same - Google Patents

Use of an anti-cd20 type II antibody useful to prepare a drug to treat a cancer that expresses cd20 in combination with a proteasome inhibitor, pharmaceutical composition containing said combination and kit of the same

Info

Publication number
CL2008003122A1
CL2008003122A1 CL2008003122A CL2008003122A CL2008003122A1 CL 2008003122 A1 CL2008003122 A1 CL 2008003122A1 CL 2008003122 A CL2008003122 A CL 2008003122A CL 2008003122 A CL2008003122 A CL 2008003122A CL 2008003122 A1 CL2008003122 A1 CL 2008003122A1
Authority
CL
Chile
Prior art keywords
combination
expresses
cancer
kit
drug
Prior art date
Application number
CL2008003122A
Other languages
Spanish (es)
Inventor
Christian Klein
Pablo Umana
George Fertig
Thomas Friess
Original Assignee
Hoffmann La Roche
Glycart Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38973774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003122(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Glycart Biotechnology Ag filed Critical Hoffmann La Roche
Publication of CL2008003122A1 publication Critical patent/CL2008003122A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de un anticuerpo anti-cd20 de tipo ii útil para preparar un medicamento para tratar un cancer que expresa cd20 en combinación con un inhibidor de proteasoma, composición farmacéutica que contiene dicha combinación y kit del mismo.Use of an anti-cd20 type II antibody useful for preparing a drug for treating a cancer that expresses cd20 in combination with a proteasome inhibitor, a pharmaceutical composition containing said combination and a kit thereof.

CL2008003122A 2007-10-24 2008-10-22 Use of an anti-cd20 type II antibody useful to prepare a drug to treat a cancer that expresses cd20 in combination with a proteasome inhibitor, pharmaceutical composition containing said combination and kit of the same CL2008003122A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07020820 2007-10-24

Publications (1)

Publication Number Publication Date
CL2008003122A1 true CL2008003122A1 (en) 2009-10-16

Family

ID=38973774

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003122A CL2008003122A1 (en) 2007-10-24 2008-10-22 Use of an anti-cd20 type II antibody useful to prepare a drug to treat a cancer that expresses cd20 in combination with a proteasome inhibitor, pharmaceutical composition containing said combination and kit of the same

Country Status (16)

Country Link
US (4) US20090110688A1 (en)
EP (1) EP2205318B1 (en)
JP (1) JP5469073B2 (en)
KR (1) KR101280733B1 (en)
AR (1) AR071733A1 (en)
AU (1) AU2008315926A1 (en)
CA (1) CA2702962C (en)
CL (1) CL2008003122A1 (en)
ES (1) ES2527775T3 (en)
IL (1) IL205025A0 (en)
MX (1) MX2010004164A (en)
PE (1) PE20090975A1 (en)
RU (1) RU2520757C2 (en)
TW (1) TW200927762A (en)
WO (1) WO2009053038A2 (en)
ZA (1) ZA201002575B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01775B (en) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
TW201438738A (en) 2008-09-16 2014-10-16 Genentech Inc Method for treating progressive multiple sclerosis
AR077867A1 (en) * 2009-08-14 2011-09-28 Roche Glycart Ag COMBINATORY THERAPY OF A CD20 ANTIBODY AFUCOSILATED WITH FLUDARABINE AND / OR MITOXANTRONE
TWI409079B (en) 2009-08-14 2013-09-21 Roche Glycart Ag Combination therapy of atypical fucosylated CD20 antibody and bendamustine
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
US8853147B2 (en) * 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
RU2585489C2 (en) * 2010-04-27 2016-05-27 Рош Гликарт Аг COMBINED THERAPY WITH AFUCOSYLATED CD20 ANTIBODY AND mTOR INHIBITOR
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
TW201208703A (en) * 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
RU2013131444A (en) * 2010-12-16 2015-01-27 Рош Гликарт Аг COMBINED THERAPY BY AFUCOSYLED ANTIBODY TO CD20 AND MDM2 INHIBITOR
WO2012135528A2 (en) * 2011-03-29 2012-10-04 Texas Tech University System Galectin-3c combination therapy for human cancer
US9856534B2 (en) 2011-04-29 2018-01-02 Emory University Selecting use of proteasome inhibitors based on NF-κB2 sequence
CA2862492A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
EP2812338A4 (en) * 2012-01-24 2015-09-23 Millennium Pharm Inc Method of treatment of nasopharyngeal caner
BR112015022210A8 (en) 2013-03-13 2018-01-23 Genentech Inc antibody formulations
JP7072384B2 (en) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド Antibody preparation
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
CN116726362A (en) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 Methods and devices for treating diseases with biologic therapeutic agents
CN115666704B (en) 2019-12-13 2025-09-26 比特比德科有限责任公司 Ingestible device for delivering therapeutic agents to the gastrointestinal tract
CN118339188A (en) 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 Heterodimeric Fc for preparing fusion proteins and bispecific antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
JP4334141B2 (en) * 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
IL149500A0 (en) * 1999-11-08 2002-11-10 Idec Pharma Corp Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
RU2306952C2 (en) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Method for treating the cases of malignant tumors containing b-cells with a combination of applications related to antibodies reducing b-cells number and with immunomodulating antibodies
ME01775B (en) * 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
EP1863513A2 (en) * 2005-03-11 2007-12-12 The University of North Carolina at Chapel Hill Potent and specific immunoproteasome inhibitors
US20110129412A1 (en) * 2005-06-02 2011-06-02 Astrazeneca Ab Antibodies Directed to CD20 and Uses Thereof
WO2007031875A2 (en) * 2005-08-26 2007-03-22 Glycart Biotechnology Ag Modified antigen binding molecules with altered cell signaling activity

Also Published As

Publication number Publication date
TW200927762A (en) 2009-07-01
PE20090975A1 (en) 2009-07-13
AU2008315926A1 (en) 2009-04-30
KR20100068292A (en) 2010-06-22
RU2010120724A (en) 2012-05-20
ZA201002575B (en) 2011-04-28
IL205025A0 (en) 2010-11-30
US20110200598A1 (en) 2011-08-18
CA2702962A1 (en) 2009-04-30
AR071733A1 (en) 2010-07-14
US20090110688A1 (en) 2009-04-30
CA2702962C (en) 2016-10-25
RU2520757C2 (en) 2014-06-27
JP2011500741A (en) 2011-01-06
JP5469073B2 (en) 2014-04-09
KR101280733B1 (en) 2013-07-02
US20160000912A1 (en) 2016-01-07
CN102083499A (en) 2011-06-01
US20120219549A1 (en) 2012-08-30
ES2527775T3 (en) 2015-01-29
WO2009053038A2 (en) 2009-04-30
WO2009053038A3 (en) 2009-06-25
EP2205318B1 (en) 2014-11-19
EP2205318A2 (en) 2010-07-14
MX2010004164A (en) 2010-08-04

Similar Documents

Publication Publication Date Title
CL2008003122A1 (en) Use of an anti-cd20 type II antibody useful to prepare a drug to treat a cancer that expresses cd20 in combination with a proteasome inhibitor, pharmaceutical composition containing said combination and kit of the same
CL2008001656A1 (en) Anti-c3b antibody; pharmaceutical composition comprising it, and its use to prevent or treat a complement-associated disorder; kit containing it.
CL2008002319A1 (en) Compounds derived from pyrrolopyrimidine; pharmaceutical composition comprising said compounds; and its use to treat cancer.
CL2008002613A1 (en) Use of a combination of an anti-cd20 type I antibody with an anti-cd20 type II antibody to treat cancer expressing cd20.
NI200900022A (en) SPECIFIC ANTIBODY OF PRLR AND USES OF THE SAME
CL2008001633A1 (en) Compounds derived from pyrrolidin-3-carboxamide; pharmaceutical composition; and use as erk inhibitors for the treatment of cancer.
ECSP20007663A (en) ANTI-CD137 ANTIBODIES
CO2019005287A2 (en) Compounds of 7-phenylethylamino-4h-pyrimido [4,5-d] [1,3] -oxazin-2-one as inhibitors of mutant idh1 and idh2
CL2011001255A1 (en) Pharmaceutical combinations comprising an antibody that specifically recognizes cd38 and at least vincristine; and use of the antibody that specifically recognizes cd38 for the treatment of cancer.
CL2011000454A1 (en) Compounds derived from picolinamide, pim kinase inhibitors, associated with tumorigenesis; pharmaceutical composition that includes them; and its use in the treatment of cancer.
CL2009000713A1 (en) Pharmaceutical composition comprising an anti-cd20 type II antibody with increased antibody-dependent cellular cytotoxicity (ccda) and one or more chemotherapeutic agents; and its use to treat a cancer that expresses cd20.
CL2008002381A1 (en) Immunostimulatory oligonucleotide; pharmaceutical composition comprising it; and its use to treat a disorder or condition in a subject, including cancer.
CL2011001232A1 (en) Pharmaceutical combination comprising an antibody that specifically recognizes cd38 and at least cytarabine; and its use for cancer treatment
CL2011000191A1 (en) Compounds derived from substituted fused pyrimidine, mtor inhibitors; pharmaceutical composition that includes it; and use in the treatment of cancer.
CR20160271A (en) PEPTIDOMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
CL2011002877A1 (en) Antibody that recognizes the fnd1 domain of the ax1 receptor; pharmaceutical composition comprising it; and its use to treat cancer.
BR112017018941B8 (en) CD20-BINDING MOLECULE, ITS USE, COMPOSITION AND METHOD IN VITRO TO DIRECTION COMPLEMENT-MEDIATED DEATH OF A CELL THAT EXPRESSES CD20
CL2007000311A1 (en) Compounds derived from chromen-2-one; pharmaceutical composition that includes them; and their use in the treatment of a proliferative disorder such as cancer.
CL2015002472A1 (en) As inhibitors of mutant idh-yl-oxazolidin-2-ones 3-pyrimidin-4.
MX2016007851A (en) Peptidomimetic compounds and antibody-drug conjugates thereof.
CL2012002319A1 (en) Compounds derived from amino-thienopyrimidines containing a substituted alkyl group, mnk inhibitors | or mnk2; pharmaceutical composition; and its use for the prophylaxis or therapy of metabolic diseases, hematopoietic disorders, neurodegenerative diseases, cancer, among others.
CL2012002189A1 (en) Compounds derived from substituted pyrrolidine-2-carboxamides; mdm2-p53 interaction inhibitors; pharmaceutical composition; and its use for the treatment of cancer, particularly solid tumors.
PA8850101A1 (en) ANTITUMORAL COMBINATIONS CONTAINING ANTIBODIES
CL2007003726A1 (en) ANTI-RECEIVER ANTIBODIES OF THE INSULIN I SIMILAR GROWTH FACTOR (IGF-IR); PHARMACEUTICAL COMPOSITION CONTAINING IT; AND ITS USE TO TREAT CANCER.
GT201300320A (en) COMBINATION THERAPY INCLUDING A CDK4 / 6 INHIBITOR AND A PI3K INHIBITOR FOR USE IN CANCER TREATMENT.